These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 25001515)
1. Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. Hellmann MA; Lev N; Lotan I; Mosberg-Galili R; Inbar E; Luckman J; Fichman-Horn S; Yakimov M; Steiner I J Neurol Sci; 2014 Sep; 344(1-2):193-7. PubMed ID: 25001515 [TBL] [Abstract][Full Text] [Related]
10. Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient. Lysandropoulos AP; Benghiat F Mult Scler; 2013 Oct; 19(11):1551-2. PubMed ID: 23817558 [No Abstract] [Full Text] [Related]
11. Fingolimod: a novel immunosuppressant for multiple sclerosis. Brown BA; Kantesaria PP; McDevitt LM Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617 [TBL] [Abstract][Full Text] [Related]
12. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Ward MD; Jones DE; Goldman MD Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480 [TBL] [Abstract][Full Text] [Related]
13. Prolonged and symptomatic bradycardia following a single dose of fingolimod. Faber H; Fischer HJ; Weber F Mult Scler; 2013 Jan; 19(1):126-8. PubMed ID: 22729989 [TBL] [Abstract][Full Text] [Related]
14. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L; Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847 [TBL] [Abstract][Full Text] [Related]
15. [Cystoid macular oedema after fingolimod treatment in multiple sclerosis]. Asensio-Sánchez VM; Trujillo-Guzmán L; Ramoa-Osorio R Arch Soc Esp Oftalmol; 2014 Mar; 89(3):104-6. PubMed ID: 24269406 [TBL] [Abstract][Full Text] [Related]
16. Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment. Rolf L; Muris AH; Damoiseaux J; van Daele M; Hupperts R Neurology; 2014 Mar; 82(11):1008-9. PubMed ID: 24523479 [No Abstract] [Full Text] [Related]
17. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. Conzett KB; Kolm I; Jelcic I; Kamarachev J; Dummer R; Braun R; French LE; Linnebank M; Hofbauer GF Arch Dermatol; 2011 Aug; 147(8):991-2. PubMed ID: 21844470 [No Abstract] [Full Text] [Related]
18. Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis. Gallego-Pinazo R; España-Gregori E; Casanova B; Pardo-López D; Díaz-Llopis M J Neuroophthalmol; 2011 Sep; 31(3):292-3. PubMed ID: 21826025 [No Abstract] [Full Text] [Related]
19. Tumefactive MS lesions under fingolimod: a case report and literature review. Pilz G; Harrer A; Wipfler P; Oppermann K; Sellner J; Fazekas F; Trinka E; Kraus J Neurology; 2013 Nov; 81(19):1654-8. PubMed ID: 24097813 [TBL] [Abstract][Full Text] [Related]
20. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]